These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 28142109)

  • 61. [Expression of interleukin-37, vascular endothelial growth factor A, and transforming growth factor-β1 and their correlation with T cells in children with primary immune thrombocytopenia].
    Tong LL; Wang LH; Fang F; Xu B; Zheng SH
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Nov; 25(11):1131-1136. PubMed ID: 37990457
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
    Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
    Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP).
    Wang JD; Chang TK; Lin HK; Huang FL; Wang CJ; Lee HJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):636-40. PubMed ID: 21721104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura.
    Guo NH; Fu X; Zi FM; Song Y; Wang S; Cheng J
    Int Immunopharmacol; 2019 Aug; 73():181-192. PubMed ID: 31102993
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan].
    Yoshida M; Kanashima H; Nakao T; Ogawa Y; Hino M; Nakane T; Ohta T; Kumura T; Manabe M; Yamamura R; Yamane T
    Rinsho Ketsueki; 2013 May; 54(5):444-50. PubMed ID: 23727682
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of Th17/Treg cells and Th cytokines in an improved immune thrombocytopenia mouse model.
    Zhang G; Zhang P; Liu H; Liu X; Xie S; Wang X; Wu Y; Chang J; Ma L
    Hematology; 2017 Sep; 22(8):493-500. PubMed ID: 28300523
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Eltrombopag for chronic immune thrombocytopenia.
    Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
    Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
    [No Abstract]   [Full Text] [Related]  

  • 71. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.
    Kapur R
    Br J Haematol; 2022 Sep; 198(5):803-804. PubMed ID: 35748239
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
    González-López TJ; Fernández-Fuertes F; Hernández-Rivas JA; Sánchez-González B; Martínez-Robles V; Alvarez-Román MT; Pérez-Rus G; Pascual C; Bernat S; Arrieta-Cerdán E; Aguilar C; Bárez A; Peñarrubia MJ; Olivera P; Fernández-Rodríguez A; de Cabo E; García-Frade LJ; González-Porras JR
    Int J Hematol; 2017 Oct; 106(4):508-516. PubMed ID: 28667351
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 76. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
    Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
    Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
    Rodeghiero F; Carli G
    Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
    Grainger JD; Thind S
    Pediatr Hematol Oncol; 2017 Mar; 34(2):73-89. PubMed ID: 28537785
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased miR-155 expression in peripheral blood mononuclear cells of primary immune thrombocytopenia patients was correlated with serum cytokine profiles.
    Qian BH; Ye X; Zhang L; Sun Y; Zhang JR; Gu ML; Qin Q; Chen J; Deng AM
    Acta Haematol; 2015; 133(3):257-63. PubMed ID: 25413124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.